Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab Combined With Becotatug Vedotin as Neoadjuvant Therapy for Locally Advanced Penile Squamous Cell Carcinoma
NCT07767266Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab, becotatug vedotin in penile squamous cell carcinoma (PSCC), sponsored by Sun Yat-sen University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pucotenlimabbecotatug vedotin
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07767266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767266.